The latest headlines across every section, pulled from official and open-access sources.
Certain AIC units require hardware updates to address potential safety concerns that could lead to a delay or loss of hemodynamic support.
R. I. Khaleel et al.
Azuma Foods International Inc., U.S.A. of Hayward, CA is recalling 545 cases of the 3 pack (5.3 oz.) Azuma Foods Brand Tako Wasabi- Seasoned Octopus with Wasabi retail packages, because they may contain undeclared fish. People who have an allergy or severe sensitivity to fish run the risk of serious
This randomized clinical trial evaluates the effectiveness of remote monitoring programs led by nurses or nurse practitioners to reduce readmissions among patients after hospitalization for sepsis or lower respiratory tract infections.
In the Research Letter titled “Distance Traveled Among Out-of-State Chicago Abortion Fund Callers,”1 published April 24, 2026, there was an error in the listed degree of a coauthor. Dr Daniel’s degree is now listed as a PhD. There were also results transposed in the Table. Results for median distance to provider for hospital and nonhospital level of care have been fixed. This article has been corrected.1
Infectious Diseases
Public Health
This cross-sectional study uses clinical trial data, US and European oncology drug approval data, and health care professional survey data to examine the representation of South American patients in sarcoma clinical trials.
This cross-sectional study characterizes internet searches for leucovorin, folinic acid, or folate after a White House announcement about autism on September 22, 2025.
This cross-sectional study investigates the geographic distribution and accessibility of clinical trials of systemic treatments for invasive fungal infections.
This randomized clinical trial compares the effectiveness and safety of topical antiseptic regimens to reduce bacterial load in the maternal genital tract and on neonatal skin for prevention of sepsis in low-income countries.
This cohort study examines waterborne transmission of Mycobacterium abscessus by whole-genome sequencing isolates from patients and health care environmental reservoirs and determining the genetic relatedness of the isolates.
This cohort study examines characteristics of artificial intelligence (AI)–enabled medical devices, including clinical study evidence, associated with US Food and Drug Administration (FDA) recall.
This qualitative study of parents of children with medical complexity explores how parents’ lived caregiving experiences shape their orientations toward life-sustaining treatment in their children.
The Digital Medicine Society launched an initiative to help payers and virtual care providers avoid common contract implementation challenges. The post DiMe Launches New Initiative for Virtual-First Care appeared first on MedCity News .
Government invests in artificial intelligence (AI) technologies to modernise the NHS and reduce waiting times.
Discover potential signals of serious risks and new safety information identified by the FDA's Adverse Event Monitoring System (AEMS). Learn how the FDA monitors and evaluates drugs for safety concerns, providing important updates on adverse events to protect public health.
On September 20, 2024, FDA requested Azurity Pharmaceuticals Inc. stop distributing unapproved drugs marketed as “Unit-of-Use Prescription Compounding Kits.
Source: National Cancer Institute - Related MedlinePlus Pages: Breast Cancer
The Food and Drug Administration is advising consumers not to purchase or use Business Pill, a product promoted and sold for male sexual enhancement on various websites, including https://supplx.com, and possibly in some retail stores.
The Food and Drug Administration is advising consumers not to purchase or use Branch Manager for Men, a product promoted and sold for male sexual enhancement on various websites, including https://supplx.com, and possibly in some retail stores.
Adoption of the GammaTile radiotherapy implant is growing, the company said, and the new funding round validates its potential to be a standard of care treatment.
Parabilis Medicines is developing a new type of peptide drug capable of hitting elusive disease targets inside cells. Cancer is the biotech’s initial focus, and the IPO cash will support lead program zolucatetide, which is in development for a rare type of tumor with limited treatment options. The post Parabilis Medicines’ Quest to Drug the Undruggable Picks Up $745M From Upsized IPO appeared first on MedCity News .
Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans